Related references
Note: Only part of the references are listed.Small molecule inhibitors of epithelial-mesenchymal transition for the treatment of cancer and fibrosis
Ya-Long Feng et al.
MEDICINAL RESEARCH REVIEWS (2020)
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer
David E. Gerber et al.
LUNG CANCER (2020)
Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy
Jeffrey C. Thompson et al.
LUNG CANCER (2020)
Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
Hanne Lind et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance
Jozsef Dudas et al.
CELLS (2020)
Cluster circulating tumor cells in surgical cases of lung cancer
Noriyoshi Sawabata et al.
GENERAL THORACIC AND CARDIOVASCULAR SURGERY (2020)
Bufalin down-regulates Axl expression to inhibit cell proliferation and induce apoptosis in non-small-cell lung cancer cells
Nam-Yi Kim et al.
BIOSCIENCE REPORTS (2020)
Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
Edyta M. Urbanska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
FHITlow/pHER2high signature in non-small cell lung cancer is predictive of anti-HER2 molecule efficacy
Jordan Da Silva et al.
JOURNAL OF PATHOLOGY (2020)
Adjuvant and Neoadjuvant Immunotherapy in Non - small Cell Lung Cancer
Stephen R. Broderick
THORACIC SURGERY CLINICS (2020)
FGFR Inhibition Enhances Sensitivity to Radiation in Non-Small Cell Lung Cancer
Gopika SenthilKumar et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer
Tatiana Shaurova et al.
FRONTIERS IN GENETICS (2020)
Guidelines and definitions for research on epithelial-mesenchymal transition
Jing Yang et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)
EMT-Associated Heterogeneity in Circulating Tumor Cells: Sticky Friends on the Road to Metastasis
Anthony Genna et al.
CANCERS (2020)
New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression
Sugandha Bhatia et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2020)
Toward Modeling Context-Specific EMT Regulatory Networks Using Temporal Single Cell RNA-Seq Data
Daniel Ramirez et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2020)
Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches
Dipesh Uprety et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Tumor Plasticity and Resistance to Immunotherapy
Lucas A. Horn et al.
TRENDS IN CANCER (2020)
Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status
Koji Fukuda et al.
CANCER RESEARCH (2019)
Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes
Deborah B. Doroshow et al.
CLINICAL CANCER RESEARCH (2019)
EMT network-based feature selection improves prognosis prediction in lung adenocarcinoma
Borong Shao et al.
PLOS ONE (2019)
Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies
Maja J. A. de Jonge et al.
TARGETED ONCOLOGY (2019)
Overexpression of fibronectin type III domain containing 3B is correlated with epithelial-mesenchymal transition and predicts poor prognosis in lung adenocarcinoma
Tingting Bian et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2019)
Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
Matthias Villalobos et al.
ONCOLOGY LETTERS (2019)
Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer
Edna Gordian et al.
Oncotarget (2019)
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours
Gabriel Mak et al.
BRITISH JOURNAL OF CANCER (2019)
Interleukin 6-triggered ataxia-telangiectasia mutated kinase activation facilitates epithelial-to-mesenchymal transition in lung cancer by upregulating vimentin expression
Yi Na Jiang et al.
EXPERIMENTAL CELL RESEARCH (2019)
A 17 gene panel for non-small-cell lung cancer prognosis identified through integrative epigenomic-transcriptomic analyses of hypoxia-induced epithelial-mesenchymal transition
Yue-Lei Chen et al.
MOLECULAR ONCOLOGY (2019)
AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells
Donghwa Kim et al.
CELL DEATH & DISEASE (2019)
Quantifying Cancer Epithelial-Mesenchymal Plasticity and its Association with Stemness and Immune Response
Dongya Jia et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy
Rama Soundararajan et al.
CANCERS (2019)
Combined Inhibition of TGF- Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models
Heng Sheng Sow et al.
CELLS (2019)
PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer
Yariswamy Manjunath et al.
CANCERS (2019)
Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC
Vera Kloten et al.
CELLS (2019)
EpCAMlow Circulating Tumor Cells: Gold in the Waste
Chiara Nicolazzo et al.
DISEASE MARKERS (2019)
Overcoming multiple drug resistance in lung cancer using siRNA targeted therapy
Sanaz Naghizadeh et al.
GENE (2019)
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy
Marzia Del Re et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer A Review
Kathryn C. Arbour et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Narjust Duma et al.
MAYO CLINIC PROCEEDINGS (2019)
Overexpression of KRT 17 promotes proliferation and invasion of non-small cell lung cancer and indicates poor prognosis
Zhao Wang et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Programmed Death-Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC
Julien Ancel et al.
CANCERS (2019)
Epigenetic Regulation of Inflammatory Cytokine-Induced Epithelial-To-Mesenchymal Cell Transition and Cancer Stem Cell Generation
Georgios S. Markopoulos et al.
CELLS (2019)
Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer
Serena De Matteis et al.
JOURNAL OF ONCOLOGY (2019)
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Haitang Yang et al.
FRONTIERS IN ONCOLOGY (2019)
Current Approaches in NSCLC Targeting K-RAS and EGFR
Veronica Aran et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer
Ying Wang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
Chenjing Zhu et al.
MOLECULAR CANCER (2019)
Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer
Feng Wang et al.
TRANSLATIONAL CANCER RESEARCH (2019)
EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer
Eugene Tulchinsky et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2019)
Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma
Diego de Miguel-Perez et al.
CANCERS (2019)
EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
Xuan Zhu et al.
FRONTIERS IN ONCOLOGY (2019)
Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers
Emily N. Arner et al.
FRONTIERS IN ONCOLOGY (2019)
Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer
Hiroshi Nokihara et al.
CLINICAL LUNG CANCER (2019)
Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer
Paul Wheatley-Price et al.
CLINICAL LUNG CANCER (2019)
Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma
Beth A. Hellerstedt et al.
CLINICAL LUNG CANCER (2019)
Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer
Jennifer W. Carlisle et al.
FUTURE ONCOLOGY (2019)
New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer
Anushka Dongre et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
EMT Transition States during Tumor Progression and Metastasis
Ievgenia Pastushenko et al.
TRENDS IN CELL BIOLOGY (2019)
Mapping lung cancer epithelial-mesenchymal transition states and trajectories with single-cell resolution
Loukia G. Karacosta et al.
NATURE COMMUNICATIONS (2019)
Wnt Signaling and Its Significance Within the Tumor Microenvironment: Novel Therapeutic Insights
Sonal Patel et al.
FRONTIERS IN IMMUNOLOGY (2019)
Circulating Tumor Cells in Diagnosis and Treatment of Lung Cancer
Vilem Maly et al.
IN VIVO (2019)
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions
Liliang Xia et al.
ONCOLOGIST (2019)
Epigenetic activation of hepatocyte growth factor is associated with epithelial-mesenchymal transition and clinical outcome in non-small cell lung cancer
Jun Yin et al.
JOURNAL OF CANCER (2019)
An Autocrine IL-6/IGF-1R Loop Mediates EMT and Promotes Tumor Growth in Non-small Cell Lung Cancer
Xianan Zheng et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2019)
Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer
Giuseppe Bronte et al.
BIOLOGICAL REVIEWS (2018)
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
Baohui Han et al.
BRITISH JOURNAL OF CANCER (2018)
Epithelial-mesenchymal transition and GALC expression of circulating tumor cells indicate metastasis and poor prognosis in non-small cell lung cancer
De-Gang Liu et al.
CANCER BIOMARKERS (2018)
CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib
Wenfeng Gou et al.
CANCER LETTERS (2018)
Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer
Ryohei Katayama
CANCER SCIENCE (2018)
Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies
Sun Min Lim et al.
CANCER TREATMENT REVIEWS (2018)
Upregulation of IL-11,an IL-6 Family Cytokine, Promotes Tumor Progression and Correlates with Poor Prognosis in Non-Small Cell Lung Cancer
Meng Zhao et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers
Kazuki Takada et al.
CLINICAL LUNG CANCER (2018)
E-cadherin: Its dysregulation in carcinogenesis and clinical implications
Sonia How Ming Wong et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
Circulating tumor cells count as a predictor of survival in lung cancer
Konstantinos Syrigos et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy
Solange Peters et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2018)
C-MET inhibitors for advanced non-small cell lung cancer
Giulia Pasquini et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Epithelial Mesenchymal Transition in Tumor Metastasis
Vivek Mittal
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13 (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?
Jente van Staalduinen et al.
ONCOGENE (2018)
Preliminary mechanisms of regulating PD-L1 expression in non-small cell lung cancer during the EMT process
Fang Li et al.
ONCOLOGY REPORTS (2018)
Molecular characterization of circulating tumor cells-from bench to bedside
Yanmeng Li et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2018)
Molecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical Practice
Annalisa Milano et al.
ANALYTICAL CELLULAR PATHOLOGY (2018)
Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC)
Young Kwang Chae et al.
SCIENTIFIC REPORTS (2018)
ALK-rearrangement in non-small-cell lung cancer (NSCLC)
Xue Du et al.
THORACIC CANCER (2018)
PD-L1 expression is regulated by both DNA methylation and NF-kappa B during EMT signaling in non-small cell lung carcinoma
A. Asgarova et al.
ONCOIMMUNOLOGY (2018)
Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis
Niki Karachaliou et al.
EBIOMEDICINE (2018)
Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers
Jiacong Wei et al.
CANCERS (2018)
First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer
C. Massard et al.
ANNALS OF ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma
Mau-Ern Poh et al.
JOURNAL OF THORACIC DISEASE (2018)
Intracellular and extracellular TGF-β signaling in cancer: some recent topics
Kohei Miyazono et al.
FRONTIERS OF MEDICINE (2018)
被撤回的出版物: The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells (Retracted article. See vol. 63, 2021)
Jiwei Guo et al.
EBIOMEDICINE (2018)
FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells
Yuwen He et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
A case of pulmonary pleomorphic carcinoma with malignant phenotypes induced by ZEB1-associated epithelial-mesenchymal transition
Mayo Kondo et al.
RESPIRATORY MEDICINE CASE REPORTS (2018)
Radiation Enhances the Epithelial- Mesenchymal Transition of A549 Cells via miR3591-5p/USP33/PPM1A
Jinhua Lu et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Epithelial-mesenchymal plasticity and circulating tumor cells: Travel companions to metastases
Marie-Emilie Francart et al.
DEVELOPMENTAL DYNAMICS (2018)
Prospects for new lung cancer treatments that target EMT signaling
Yuji Otsuki et al.
DEVELOPMENTAL DYNAMICS (2018)
Epithelial-mesenchymal plasticity in circulating tumor cells
Catherine Alix-Panabieres et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2017)
Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition
Q. Zhang et al.
ONCOGENE (2017)
Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1
Takaaki Ito et al.
HUMAN CELL (2017)
Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer
Pietro Fici et al.
ONCOTARGET (2017)
Circulating tumor cells: clinical validity and utility
Luc Cabel et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2017)
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Alexander Drilon et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer
Xiaomei Gong et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Recent Advances in Targeting ROS1 in Lung Cancer
Jessica J. Lin et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch et al.
LANCET (2017)
Chemotherapeutics-resistance arms race: An update on mechanisms involved in resistance limiting EGFR inhibitors in lung cancer
Pankaj Kumar Singh et al.
LIFE SCIENCES (2017)
Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells
Yuichi Sesumi et al.
LUNG CANCER (2017)
Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer
Soichiro Funaki et al.
ONCOLOGY REPORTS (2017)
Epithelial-mesenchymal transition and inflammation at the site of the primary tumor
Charli Dominguez et al.
SEMINARS IN CANCER BIOLOGY (2017)
Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients
Shinsaku Togo et al.
ONCOTARGET (2017)
Circulating tumor cells in early stage lung adenocarcinoma: a case series report and literature review
Xu-Rui Jin et al.
ONCOTARGET (2017)
PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer
Lujun Chen et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition
Nana Zhang et al.
RESPIRATORY MEDICINE CASE REPORTS (2017)
Understanding and targeting resistance mechanisms in NSCLC
Julia Rotow et al.
NATURE REVIEWS CANCER (2017)
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers
Paul K. Paik et al.
CLINICAL CANCER RESEARCH (2017)
Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer
S. Li et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2017)
AXL-Driven EMT State as a Targetable Conduit in Cancer
Jane Antony et al.
CANCER RESEARCH (2017)
A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups
C. R. Lindsay et al.
ANNALS OF ONCOLOGY (2017)
PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer
Riki Okita et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer
Nikolaos Tsoukalas et al.
ANTICANCER RESEARCH (2017)
A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer
Heather A. Wakelee et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition
Milena P. Mak et al.
CLINICAL CANCER RESEARCH (2016)
Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells
Mei-ling Han et al.
ACTA PHARMACOLOGICA SINICA (2016)
BRAF and Epithelial-Mesenchymal Transition: Lessons From Papillary Thyroid Carcinoma and Primary Cutaneous Melanoma
Brendon Mitchell et al.
ADVANCES IN ANATOMIC PATHOLOGY (2016)
Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT
Colin Charles Tieche et al.
BMC CANCER (2016)
Axl Receptor Axis: A New Therapeutic Target in Lung Cancer
Pavel A. Levin et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
Peter Goldstraw et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial
Joel W. Neal et al.
LANCET ONCOLOGY (2016)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Justin F. Gainor et al.
CANCER DISCOVERY (2016)
PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma
Chan-Young Ock et al.
ONCOTARGET (2016)
Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1
Claudia Voena et al.
ONCOTARGET (2016)
miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET
Qing-yong Chen et al.
ONCOTARGET (2016)
Attenuated LKB1-SIK1 signaling promotes epithelial-mesenchymal transition and radioresistance of non-small cell lung cancer cells
Yuan-Hu Yao et al.
CHINESE JOURNAL OF CANCER (2016)
Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer
Karen L. Reckamp et al.
CANCER (2015)
Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition
Margaret Soucheray et al.
CANCER RESEARCH (2015)
A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer
G. Giaccone et al.
EUROPEAN JOURNAL OF CANCER (2015)
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia
Ivan Diaz-Padilla et al.
GYNECOLOGIC ONCOLOGY (2015)
Critical contribution of MCL-1 in EMT-associated chemo-resistance in A549 non-small cell lung cancer
Masayoshi Toge et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Clinicopathological analysis of pleomorphic carcinoma of the lung: Diffuse ZEB1 expression predicts poor survival
So Miyahara et al.
LUNG CANCER (2015)
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
Wendy A. Cooper et al.
LUNG CANCER (2015)
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance
Kari R. Fischer et al.
NATURE (2015)
High EMT Signature Score of Invasive Non-Small Cell Lung Cancer (NSCLC) Cells Correlates with NFκB Driven Colony-Stimulating Factor 2 (CSF2/GM-CSF) Secretion by Neighboring Stromal Fibroblasts
Albin Rudisch et al.
PLOS ONE (2015)
Decreased expression of claudin-3 is associated with a poor prognosis and EMT in completely resected squamous cell lung carcinoma
Juanjuan Che et al.
TUMOR BIOLOGY (2015)
A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
Seigo Miyoshi et al.
ONCOTARGETS AND THERAPY (2015)
Blocking the epithelial-to-mesenchymal transition pathway abrogates resistance to anti-folate chemotherapy in lung cancer
S-Q Liang et al.
CELL DEATH & DISEASE (2015)
Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer
Juan Zhou et al.
ONCOTARGET (2015)
Epithelial Plasticity in Cancer: Unmasking a MicroRNA Network for TGF-β-, Notch-, and Wnt-Mediated EMT
Eugenio Zoni et al.
JOURNAL OF ONCOLOGY (2015)
Classification of Circulating Tumor Cells by Epithelial-Mesenchymal Transition Markers
Shiyang Wu et al.
PLOS ONE (2015)
Intratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasis
Deepika Neelakantan et al.
CELL ADHESION & MIGRATION (2015)
The Role of Vimentin Intermediate Filaments in the Progression of Lung Cancer
Martha E. Kidd et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2014)
Prognostic and diagnostic value of epithelial to mesenchymal transition markers in pulmonary neuroendocrine tumors
Jose A. Galvan et al.
BMC CANCER (2014)
MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc
Dongqin Chen et al.
EUROPEAN JOURNAL OF CANCER (2014)
The hypoxic tumor microenvironment: driving the tumorigenesis of non-small-cell lung cancer
John G. Foster et al.
FUTURE ONCOLOGY (2014)
Twist-1 Up-Regulation in Carcinoma Correlates to Poor Survival
Alimujiang Wushou et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
Gemcitabine inhibits the micrometastasis of non-small cell lung cancer by targeting the EpCAM-positive circulating tumor cells via the HGF/cMET pathway
Z. J. Liao et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition
Akihiro Kogita et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma
Ana De Jesus-Acosta et al.
INVESTIGATIONAL NEW DRUGS (2014)
Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application
Xun Yuan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
FGF Receptors: Cancer Biology and Therapeutics
Masaru Katoh et al.
MEDICINAL RESEARCH REVIEWS (2014)
Multilayer control of the EMT master regulators
H. Zheng et al.
ONCOGENE (2014)
Immunohistochemical analysis of the expression of E-cadherin and ZEB1 in non-small cell lung cancer
Daisuke Matsubara et al.
PATHOLOGY INTERNATIONAL (2014)
Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer
Y. Wang et al.
CELL DEATH & DISEASE (2014)
Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway
Alexis B. Cortot et al.
CANCER RESEARCH (2013)
Cisplatin influences acquisition of resistance to molecular-targeted agents through epithelial-mesenchymal transition-like changes
Maki Kurokawa et al.
CANCER SCIENCE (2013)
An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers et al.
CLINICAL CANCER RESEARCH (2013)
Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo
Mian Xie et al.
EUROPEAN JOURNAL OF CANCER (2013)
Rhamnetin and Cirsiliol Induce Radiosensitization and Inhibition of Epithelial-Mesenchymal Transition (EMT) by miR-34a-mediated Suppression of Notch-1 Expression in Non-small Cell Lung Cancer Cell Lines
JiHoon Kang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma
Hua Zhang et al.
JOURNAL OF CLINICAL PATHOLOGY (2013)
Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes
Roberto Gomez-Casal et al.
MOLECULAR CANCER (2013)
Vimentin expression predicts the occurrence of metastases in non small cell lung carcinomas
Maryline Dauphin et al.
LUNG CANCER (2013)
Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy
Samir E. Witta et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
Tudor Ciuleanu et al.
LANCET ONCOLOGY (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
Epithelial-mesenchymal transition in pulmonary carcinosarcoma: case report and literature review
Vibha T. Thomas et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2012)
Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib
Kenichi Suda et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma
Alexandra Schramm et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2010)
A Gene Expression Signature Associated with K-Ras Addiction Reveals Regulators of EMT and Tumor Cell Survival
Anurag Singh et al.
CANCER CELL (2009)
Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression
Don L. Gibbons et al.
GENES & DEVELOPMENT (2009)
Biomarkers for epithelial-mesenchymal transitions
Michael Zeisberg et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line
Jin Kyung Rho et al.
LUNG CANCER (2009)
Prognostic significance of hypoxia-inducible factor-1α, TWIST1 and Snail expression in resectable non-small cell lung cancer
J-J Hung et al.
THORAX (2009)
TWIST activation by hypoxia inducible factor-1 (HIF-1)
Muh-Hwa Yang et al.
CELL CYCLE (2008)
Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin
Karen L. Reckamp et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Ionising radiation induces changes associated with epithelial-mesenchymal transdifferentiation and increased cell motility of A549 lung epithelial cells
Jae-Won Jung et al.
EUROPEAN JOURNAL OF CANCER (2007)
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines
SE Witta et al.
CANCER RESEARCH (2006)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
